List view / Grid view
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
This award recognises outstanding achievements of female researchers in the life sciences in the past five years.
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
GE BioPark Cork, subject to contract and planning approvals, will feature Europe’s first KUBio, prefabricated, off-the-shelf bio-manufacturing facilities...
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The investment will be used for manufacturing of new respiratory and biopharmaceuticals, to be exported outside the UK to global markets...
Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...
